1 day Ago By ABMN Staff
CANADA LIFE ASSURANCE Co boosted its position in shares of BioNTech SE ( NASDAQ:BNTX – Free Report ) by 63.5% in the 4th quarter, HoldingsChannel reports. The fund owned 7,791 shares of the company’s stock after acquiring an additional 3,025 shares during the period.
CANADA LIFE ASSURANCE Co’s holdings in BioNTech were worth $887,000 as of its most recent SEC filing. Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in BioNTech by 412.
3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after acquiring an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new position in shares of BioNTech in the 4th quarter valued at $684,000.
Bank of New York Mellon Corp boosted its holdings in shares of BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares in the last quarter.
C2P Capital Advisory Group LLC d.b.a.
Prosperity Capital Advisors acquired a new position in shares of BioNTech in the 4th quarter valued at $1,118,000. Finally, Retireful LLC acquired a new position in shares of BioNTech in the 4th quarter valued at $260,000. Institutional investors and hedge funds own 15.
52% of the company’s stock. BioNTech Price Performance BNTX stock opened at $104.00 on Wednesday.
The company has a fifty day moving average of $101.14 and a 200-day moving average of $110.38.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.
33. The stock has a market capitalization of $24.96 billion, a PE ratio of -49.
52 and a beta of 1.07. BioNTech SE has a one year low of $76.
53 and a one year high of $131.49. Analyst Ratings Changes Several brokerages have recently issued reports on BNTX.
HC Wainwright lowered their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday, April 1st.
Citigroup assumed coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 target price for the company.
Truist Financial assumed coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company.
Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th.
Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock.
According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $143.44. Read Our Latest Stock Analysis on BNTX BioNTech Profile ( Free Report ) BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. Featured Articles Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE ( NASDAQ:BNTX – Free Report ).
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter ..
